CAS 88431-47-4 Human Growth Hormone Peptide Erythropoietin EPO For Blood Cells Hemopoietin

CAS 88431-47-4 Erythropoietin EPO 3000iu/vial For Blood Cells Hemopoietin

Product Details:

EPO(Erythropoietin)
EPO(Erythropoietin) Powder 3000iu/vial, 5vials/kit
EPO(Erythropoietin) Injection 3000iu/vial, 5vials/kit
CAS:88431-47-4
Appearance: White Freeze dried Powder/ Injection

Description:

Erythropoietin (EPO) is a glycoprotein hormone of 34–38 kDa which stimulates proliferation and differentiation of erythroid precursor cells (CFU-E, BFU-E) to more mature erythrocytes. EPO is primarily produced in adult kidney and fetal liver cells. Cells responsive to EPO have been identified in adult bone marrow, fetal liver or adult spleen. In cultures of erythropoietic progenitor cells, EPO stimulates the proliferation and differentiation of these cells to more mature red blood cells.
Erythropoietin (EPO) regulates the level of erythrocytes in response to the level of oxygen in the blood. When tissues meet hypoxic conditions, the EPO level in the blood increases, and the elevated EPO level triggers differentiation of progenitor cells in bone marrow and release of erythrocytes from bone marrow into the blood.

Also known as hematopoietin or hemopoietin, EPO is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and tubular epithelial tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. In addition to erythropoiesis, erythropoietin also has other known biological functions. For example, it plays an important role in the brain's response to neuronal injury. EPO is also involved in the wound healing process.

Uses:

Erythropoietin is available as a therapeutic agent produced by recombinant DNA technology in mammalian cell culture. It is used in treating anemia resulting from chronic kidney disease and myelodysplasia, from the treatment of cancer (chemotherapy and radiation). Current research suggests that, aminoacid R103 to E mutation in Erythropoietin makes it Neuroprotective and non-erythropoietic.

rhEPO should be used under instruction of physicians. It may be administrated subcutaneously or intravenously, 2-3 times per week. The dosage should be adjusted according to the severity of anemia, age and other related factors.

​

COA:

History:

Haematologist John Adamson and nephrologist Joseph W. Eschbach looked at various forms of renal failure and the role of the natural hormone EPO in the formation of red blood cells. Studying sheep and other animals in the 1970s, the two scientists helped establish that EPO stimulates the production of red cells in bone marrow and could lead to a treatment for anemia in humans. In 1968, Goldwasser and Kung began work to purify human EPO, and managed to purify milligram quantities of over 95% pure material by 1977.Pure EPO allowed the amino acid sequence to be partially identified and the gene to be isolated.Later an NIH-funded researcher at Columbia University discovered a way to synthesize EPO. Columbia University patented the technique, and licensed it to Amgen. Controversy has ensued over the fairness of the rewards that Amgen reaped from NIH-funded work, and Goldwasser was never financially rewarded for his work.

Our Advantage: